Nuvation Bio to Participate in Upcoming Investor Conferences
Nuvation Bio (NYSE: NUVB) announced that CEO David Hung, M.D., and CFO Philippe Sauvage will attend four investor conferences in March 2026 with fireside chats at TD Cowen and Citizens Life Sciences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuvation Bio (NYSE: NUVB) announced that CEO David Hung, M.D., and CFO Philippe Sauvage will attend four investor conferences in March 2026 with fireside chats at TD Cowen and Citizens Life Sciences. Fireside chat dates: March 4 and March 11, 2026. Live webcasts and archived recordings (90 days) will be available on the company Investor Relations website.
Details
News Market Reaction – NUVB
On Feb 26, the first trading day after this news, NUVB closed 4.32% above the previous close.
Data tracked by StockTitan Argus for the Feb 26 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The management team will participate in fireside chats and one-on-one meetings at the following conferences:
- TD Cowen 46th Annual Health Care Conference – fireside chat on Wednesday, March 4, 2026, at 10:30 a.m. ET in
Boston, MA - The Citizens Life Sciences Conference – fireside chat on Wednesday, March 11, 2026, at 8:25 a.m. ET in
Miami, FL
The management team will participate in one-on-one meetings only at the following conferences:
- UBS Biotech Summit Miami: Catalyst for Change on Monday, March 9, 2026, in
Miami, FL - Jefferies Biotech on the Beach Summit on Tuesday, March 10, 2026, in
Miami, FL
Live webcasts of each fireside chat will be available on the Investor Relations section of the Nuvation Bio website. An archived recording will be available for 90 days following each event.
About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI ®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; NUV-868, a BD2-selective BET inhibitor; and an innovative drug-drug conjugate (DDC) program.
Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in
Media and Investor Contacts
Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com
Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-to-participate-in-upcoming-investor-conferences-302697197.html
SOURCE Nuvation Bio Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.